Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 501–600 of 1,004

Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 115
Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers
Ortíz-Quintero, B. (2016) · Cell Proliferation · doi:10.1111/cpr.12262 · Cited by 114
Endogenous T cells prevent tumor immune escape following adoptive T cell therapy
Walsh, S. R., Simovic, B., Chen, L., Bastin, D. J., Nguyen, A., Stephenson, K. B., Mandur, T. S., Bramson, J. L., Lichty, B. D., & Wan, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126199 · Cited by 113
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
Activation and antitumor immunity of CD8 + T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid
Liu, Y., Wang, F., Peng, D., Zhang, D., Liu, L., Wei, J., Yuan, J., Zhao, L., Jiang, H., Zhang, T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk7399 · Cited by 127
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Melaiu, O., Mina, M., Chierici, M., Boldrini, R., Jurman, G., Romania, P., D’Alicandro, V., Benedetti, M. C., Castellano, A., Liu, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2601 · Cited by 113
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer
Lee, J., Won, H. S., Sun, D. S., Hong, J. H., & Ko, Y. H. (2018) · Medicine · doi:10.1097/md.0000000000011769 · Cited by 112
Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications
Wagner, M., & Wiig, H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00115 · Cited by 114
Engineering Breast Cancer Microenvironments and 3D Bioprinting
Belgodere, J. A., King, C. T., Bursavich, J. B., Burow, M. E., Martin, E. C., & Jung, J. P. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00066 · Cited by 114
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Yuan, W., Zhao, Q., Gao, Z., Lao, X., Lin, W., Chen, D., Mu, M., Huang, C.-X., Liu, Z., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 114
Corn-like Au/Ag nanorod-mediated NIR-II photothermal/photodynamic therapy potentiates immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment
Jin, L., Shen, S., Huang, Y., Li, D., & Yang, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120582 · Cited by 111
Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
Wang, B., Tang, M., Yuan, Z., Li, Z., Hu, B., Bai, X., Chu, J., Xu, X., & Zhang, X.-Q. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.026 · Cited by 112
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model
Ma, S.-D., Xu, X., Jones, R., Delecluse, H., Zumwalde, N. A., Sharma, A., Gumperz, J. E., & Kenney, S. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005642 · Cited by 111
Comparing the effects of different cell death programs in tumor progression and immunotherapy
Messmer, M. N., Snyder, A. G., & Oberst, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0214-4 · Cited by 109
Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors
Viitala, M., Virtakoivu, R., Tadayon, S., Rannikko, J. H., Jalkanen, S., & Hollmén, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3016 · Cited by 110
The Role of the Immune System in Cutaneous Squamous Cell Carcinoma
Bottomley, M. J., Thomson, J., Harwood, C. A., & Leigh, I. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082009 · Cited by 109
Agonistic CD40 Antibodies in Cancer Treatment
Djureinovic, D., Wang, M., & Kluger, H. M. (2021) · Cancers · doi:10.3390/cancers13061302 · Cited by 113
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Geuijen, C. A. W., Tacken, P. J., Wang, L.-C., Klooster, R., van Loo, P. F., Zhou, J., Mondal, A., Liu, Y.-B., Kramer, A., Condamine, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24767-5 · Cited by 114
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
Duong, C. P. M., Yong, C. S. M., Kershaw, M. H., Slaney, C. Y., & Darcy, P. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.12.009 · Cited by 112
Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer
Choi, Y., Kim, J. W., Nam, K. H., Han, S.-H., Kim, J., Ahn, S.-H., Park, D. J., Lee, K., Lee, H. S., & Kim, H. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0642-0 · Cited by 110
A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
Li, X., Wang, X., Ito, A., & Tsuji, N. M. (2020) · Nature Communications · doi:10.1038/s41467-020-17637-z · Cited by 111
Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy
Pan, H., Zheng, M., Ma, A.-Q., Liu, L., & Cai, L. (2021) · Advanced Materials · doi:10.1002/adma.202100241 · Cited by 109
Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment
Zhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 116
Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model
Lu, Y., Miao, L., Wang, Y., Xu, Z., Zhao, Y. D., Shen, Y., Xiang, G., & Huang, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.165 · Cited by 108
Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status
Song, M., Nishihara, R., Wang, M., Chan, A. T., Qian, Z. R., Inamura, K., Zhang, X., Ng, K., Kim, S. A., Mima, K., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308852 · Cited by 109
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 111
Spatial and phenotypic immune profiling of metastatic colon cancer
Lazarus, J., Maj, T., Smith, J. J., Lanfranca, M. P., Rao, A. U. K., D'Angelica, M. I., Delrosario, L., Girgis, A. A., Schukow, C. P., Shia, J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121932 · Cited by 108
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 116
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Curran, E. K., Godfrey, J. K., & Kline, J. P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.004 · Cited by 108
Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer
Hou, Y., Chao, Y., Hsieh, M.-H., Tung, H., Wang, H., & Shan, Y. (2019) · Cancers · doi:10.3390/cancers11040541 · Cited by 109
An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma
Ács, B., Ahmed, F. S., Gupta, S., Wong, P. F., Gartrell, R. D., Pradhan, J. S., Rizk, E. M., Rothberg, B. G., Saenger, Y. M., & Rimm, D. L. (2019) · Nature Communications · doi:10.1038/s41467-019-13043-2 · Cited by 105
CD45RO-CD8+ T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERβ/miR-765/PLP2/Notch axis
Zhou, W., Zhang, J., Xie, F., Wu, J., Ye, J., Wang, J., Wu, K., & Li, M. (2021) · Theranostics · doi:10.7150/thno.58337 · Cited by 107
Prognostic value of B cells in cutaneous melanoma
Selitsky, S. R., Mose, L. E., Smith, C. C., Chai, S., Hoadley, K. A., Dittmer, D. P., Moschos, S. J., Parker, J. S., & Vincent, B. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0647-5 · Cited by 111
Tumour Microenvironment (TME) Characterization Identified Prognosis and Immunotherapy Response in Muscle-Invasive Bladder Cancer (MIBC)
Cao, R., Yuan, L., Ma, B., Wang, G., Qiu, W., & Tian, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02649-x · Cited by 106
The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity
Zhou, J., Kryczek, I., Li, S., Xiong, L., Aguilar, A., Wei, S., Grove, S., Vatan, L., Yu, J., Yan, Y., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00888-3 · Cited by 107
Therapeutic Cancer Vaccines
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 103
Immune cell profiling in cancer: molecular approaches to cell-specific identification
Lyons, Y. A., Wu, S. Y., Overwijk, W. W., Baggerly, K., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0031-0 · Cited by 106
The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 110
Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer
Li, Y., Liu, X., Pan, W., Li, N., & Tang, B. (2019) · Chemical Communications · doi:10.1039/c9cc08447a · Cited by 104
Towards a consensus definition of immune exclusion in cancer
Tiwari, A., Oravecz, T., Dillon, L. A. L., Italiano, A., Audoly, L., Fridman, W. H., & Clifton, G. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084887 · Cited by 117
Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy
Chen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Tertiary Lymphoid Organs in Cancer Tissues
Hiraoka, N., Ino, Y., & Yamazaki–Itoh, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00244 · Cited by 109
Cell-mediated delivery of synthetic nano- and microparticles
Ayer, M., & Klok, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.048 · Cited by 105
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 108
Biodegradable Fe-Doped Vanadium Disulfide Theranostic Nanosheets for Enhanced Sonodynamic/Chemodynamic Therapy
Lei, H., Wang, X., Bai, S., Gong, F., Yang, N., Gong, Y., Hou, L., Cao, M., Liu, Z., & Cheng, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14647 · Cited by 104
Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer
Chen, J., Sun, H.-W., Yang, Y., Chen, H., Yu, X.-J., Wu, W., Xu, Y.-T., Jin, L.-L., Wu, X., Xu, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00377-3 · Cited by 105
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Kumar, S., Zeng, Z., Bagati, A., Tay, R. E., Sanz, L. A., Hartono, S. R., Ito, Y., Abderazzaq, F. O., Hatchi, E., Jiang, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1144 · Cited by 106
Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
An, H. J., Chon, H. J., & Kim, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179414 · Cited by 107
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 108
Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response
Xia, X., Mai, J., Xu, R., Perez, J. E. T., Guevara, M. L., Shen, Q., Mu, C., Tung, H.-Y., Corry, D. B., Evans, S. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.009 · Cited by 103
Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma
Ouyang, F., Wu, R., Yuan, W., Liu, R., Yang, D., Xiao, C., Zheng, L., Li, B., Lao, X., & Kuang, D. (2016) · Nature Communications · doi:10.1038/ncomms13453 · Cited by 102
Cancer Metabolism: Fueling More than Just Growth
Lee, N., & Kim, D. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.0310 · Cited by 102
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
Brück, O. E., Blom, S., Dufva, O., Turkki, R., Chheda, H., Ribeiro, A., Kovanen, P. E., Aittokallio, T. A., Koskenvesa, P., Kallioniemi, O., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0175-0 · Cited by 102
Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2
Elling, R., Robinson, E. K., Shapleigh, B., Liapis, S. C., Covarrubias, S., Katzman, S. J., Groff, A. F., Jiang, Z., Agarwal, S., Motwani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.027 · Cited by 103
Biomimetic micro/nano structures for biomedical applications
Xiang, T., Hou, J., Xie, H. Q., Liu, X., Gong, T., & Zhou, S. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100980 · Cited by 103
Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment
Fan, H., & Guo, Z. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215027 · Cited by 104
Several immune escape patterns in non-Hodgkin's lymphomas
Laurent, C., Charmpi, K., Gravelle, P., Tosolini, M., Franchet, C., Ysebaert, L., Brousset, P., Bidaut, A., Ycart, B., & Fournié, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026530 · Cited by 101
The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process
Wu, C., Wang, H., Ling, S., & Lu, X. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054842 · Cited by 106
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 106
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells
Iraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Araya, R. E., Ziblat, A., Domaica, C. I., Sierra, J. M., Núñez, S. Y., Secchiari, F., Gajewski, T. F., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502291 · Cited by 105
Self-citation
3D Cancer Models: The Need for a Complex Stroma, Compartmentalization and Stiffness
Pape, J., Emberton, M., & Cheema, U. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.660502 · Cited by 99
Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival
Brunner, S. M., Rubner, C., Kesselring, R., Martin, M. P., Griesshammer, E., Ruemmele, P., Stempfl, T., Teufel, A., Schlitt, H. J., & Fichtner‐Feigl, S. (2015) · Hepatology · doi:10.1002/hep.27728 · Cited by 101
Metformin and cancer immunity
Ma, R., Yi, B., Riker, A. I., & Xi, Y. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00508-0 · Cited by 104
NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis
Ju, Q., Li, X., Zhang, H., Yan, S., Li, Y., & Zhao, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3580719 · Cited by 102
The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression
Benito‐Martín, A., Giannatale, A. D., Ceder, S., & Peinado, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00066 · Cited by 101
The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models
Dakup, P., Porter, K. I., Little, A., Gajula, R. P., Zhang, H., Skornyakov, E., Kemp, M. G., Dongen, H. P. A. V., & Gaddameedhi, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24539 · Cited by 101
The immune cell atlas of human neuroblastoma
Verhoeven, B. M., Mei, S., Olsen, T. K., Gustafsson, K. U., Valind, A., Lindström, A., Gisselsson, D., Fard, S. S., Hagerling, C., Kharchenko, P. V., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100657 · Cited by 100
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
Xu-Monette, Z. Y., Li, L., Byrd, J. C., Jabbar, K. J., Manyam, G. C., de Winde, C. M., van den Brand, M., Tzankov, A., Visco, C., Wang, J., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715094 · Cited by 107
SMAD4 promotes TGF-β–independent NK cell homeostasis and maturation and antitumor immunity
Wang, Y., Chu, J., Yi, P., Dong, W., Saultz, J. N., Wang, Y., Wang, H., Scoville, S. D., Zhang, J., Wu, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121227 · Cited by 100
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
Taylor, M. A., Hughes, A. M., Walton, J. B., Coenen-Stass, A. M. L., Magiera, Ł., Mooney, L. M., Bell, S., Staniszewska, A. D., Sandin, L. C., Barry, S. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0794-7 · Cited by 98
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
The evolving landscape of N6-methyladenosine modification in the tumor microenvironment
Gu, Y., Wu, X., Zhang, J., Fang, Y., Pan, Y., Shu, Y., & Ma, P. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.009 · Cited by 98
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma
Barras, D., Ghisoni, E., Chiffelle, J., Orcurto, A., Dagher, J., Fahr, N., Benedetti, F., Crespo, I., Grimm, A. J., Morotti, M., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adg7995 · Cited by 105
Effective Delivery of Antigen–Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection
Choi, B., Moon, H., Hong, S. J., Shin, C., Do, Y., Ryu, S., & Kang, S. (2016) · ACS Nano · doi:10.1021/acsnano.5b08084 · Cited by 98
Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
Cubillos‐Ruiz, J. R., Mohamed, E. T., & Rodrı́guez, P. C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0203-4 · Cited by 98
Cerenkov Luminescence-Induced NO Release from 32P-Labeled ZnFe(CN)5NO Nanosheets to Enhance Radioisotope-Immunotherapy
Tian, L., Wang, Y., Sun, L., Xu, J., Chao, Y., Yang, K., Wang, S., & Liu, Z. (2019) · Matter · doi:10.1016/j.matt.2019.07.007 · Cited by 97
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
Kristensen, L. K., Fröhlich, C., Christensen, C. L., Melander, M. C., Poulsen, T. T., Galler, G. R., Lantto, J., Horak, I. D., Kragh, M., Nielsen, C. H., et al. (2019) · Theranostics · doi:10.7150/thno.37513 · Cited by 98
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer
Zhang, X., Wang, Y., Fan, J., Chen, W., Luan, J., Mei, X., Wang, S., Li, Y., Ye, L., Li, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0812-9 · Cited by 95
Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity
Wu, W., Pu, Y., Yao, H., Lin, H., & Shi, J. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101377 · Cited by 98
Current and promising applications of Hf( iv )-based MOFs in clinical cancer therapy
Chen, X., Li, M., Lin, M., Lu, C., Kumar, A., Pan, Y. H., Liu, J., & Peng, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00267e · Cited by 97
Chemokine (C‐X‐C motif) receptor 3–positive B cells link interleukin‐17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma
Liu, R., Yuan, W., Zeng, Q., Chan, K., Xiao, C., Zhao, X., Chen, M., Ouyang, F., Chen, D., Zheng, L., et al. (2015) · Hepatology · doi:10.1002/hep.28020 · Cited by 97
Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages
Zhang, Y., Wu, L., Li, Z., Zhang, W., Luo, F., Chu, Y., & Chen, G. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00305 · Cited by 95
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance
Li, X., Liu, Z., Zhang, A., Han, C., Shen, A., Jiang, L., Boothman, D. A., Qiao, J., Wang, Y., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11238-1 · Cited by 95
Self-citation
A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting
Sharifi, L., Nowroozi, M. R., Amini, E., Kourosh‐Arami, M., Ayati, M., & Mohsenzadegan, M. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105880 · Cited by 96
Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
Qi, X., Yang, M. J., Ma, L., Sauer, M. A., Avella, D. M., Kaifi, J. T., Bryan, J. N., Cheng, K., Staveley-O’Carroll, K. F., Kimchi, E. T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001038 · Cited by 96
Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101
Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets
Nazeri, E., Gouran‐Savadkoohi, M., Majidzadeh‐A, K., & Esmaeili, R. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.001 · Cited by 95
Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease
Ahn‐Jarvis, J. H., Parihar, A., & Doseff, A. I. (2019) · Antioxidants · doi:10.3390/antiox8070202 · Cited by 101
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Bo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 94
RNA Editing in Pathogenesis of Cancer
Baysal, B. E., Sharma, S., Hashemikhabir, S., & Janga, S. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0520 · Cited by 90
Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization
Bohner, P., Chevalier, M. F., Cesson, V., Rodrigues-Dias, S.-C., Dartiguenave, F., Burruni, R., Tawadros, T., Massimo Valerio, A., Lucca, I., Nardelli‐Haefliger, D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00622 · Cited by 94
New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
Wang, Y., Zhao, N., Wu, Z., Pan, N., Shen, X., Liu, T., Wei, F., You, J., Xu, W., & Ren, X. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04500-7 · Cited by 97
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Parisi, G., Saco, J. D., Salazar, F. B., Tsoi, J., Krystofinski, P. E., Puig-Saus, C., Zhang, R., Zhou, J., Cheung-Lau, G. C., Garcia, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-12901-3 · Cited by 94
Nanoparticle mediated cancer immunotherapy
Gupta, J., Safdari, H. A., & Hoque, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.015 · Cited by 94
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 96
Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 105
Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients
Laurent, C., Fabiani, B., Do, C., Tchernonog, E., Cartron, G., Gravelle, P., Amara, N., Malot, S., Palisoc, M., Copie‐Bergman, C., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.141978 · Cited by 94
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome
Hazama, S., Nakamura, Y., Takenouchi, H., Suzuki, N., Tsunedomi, R., Inoue, Y., Tokuhisa, Y., Iizuka, N., Yoshino, S., Takeda, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-63 · Cited by 94
Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients
Chen, J., Zheng, D.-X., Yu, X.-J., Sun, H.-W., Xu, Y.-T., Zhang, Y., & Xu, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652540 · Cited by 94

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks